SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Cipla's animal healthcare product infringes patent: US court

30 Jun 2011 Evaluate

Cipla has received an order from US court, ruling that sales of its animal healthcare product allegedly infringed a patent held by Merial. The sales of the PetArmor Plus have been suspended in the US. The company is in process of filling appeal against the order.

The company’s net profit for the quarter ended March 31, 2011 has declined by 22.33% at Rs 214.00 crore as compared to Rs 275.53 crore for the quarter ended March 31, 2010. Its total income has increased by 19% to Rs 1689.55 crore for the quarter under review from Rs 1419.77 crore in the corresponding previous quarter.

Cipla Share Price

1228.90 -9.40 (-0.76%)
20-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1668.00
Dr. Reddys Lab 1232.25
Cipla 1228.90
Zydus Lifesciences 936.35
Lupin 2328.60
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×